Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial - Nature
Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial Nature
Non-Hodgkin Lymphoma News
7 Signs of Non-Hodgkin Lymphoma You Shouldn’t Ignore - Hartford Hospital
7 Signs of Non-Hodgkin Lymphoma You Shouldn’t Ignore Hartford Hospital
Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma: a pooled analysis of four prospective cohorts - Nature
Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma: a pooled analysis of four prospective cohorts Nature
Targeted Drug Therapy for Non-Hodgkin Lymphoma - American Cancer Society
Targeted Drug Therapy for Non-Hodgkin Lymphoma American Cancer Society
Early Data Support Off-the-Shelf Englumafusp Alfa/Glofitamab in B-NHL - Targeted Oncology
Early Data Support Off-the-Shelf Englumafusp Alfa/Glofitamab in B-NHL Targeted Oncology
Hodgkin vs. Non-Hodgkin Lymphoma: How To Tell the Difference - Health: Trusted and Empathetic Health and Wellness Information
Hodgkin vs. Non-Hodgkin Lymphoma: How To Tell the Difference Health: Trusted and Empathetic Health and Wellness Information
Study reveals promising new therapy for non-Hodgkin lymphoma - Medical Xpress
Study reveals promising new therapy for non-Hodgkin lymphoma Medical Xpress
Oncology Nurse Faces Stage 4 Lymphoma Diagnosis — and Returns Stronger - Cure Today
Oncology Nurse Faces Stage 4 Lymphoma Diagnosis — and Returns Stronger Cure Today
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL - OncLive
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL OncLive
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates - Iowa Capital Dispatch
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates Iowa Capital Dispatch
New long-term analysis suggests follicular lymphoma can be cured - Fred Hutchinson Cancer Center
New long-term analysis suggests follicular lymphoma can be cured Fred Hutchinson Cancer Center
Roche’s Englumafusp Plus Glofitamab Combination Shows Why Phase 1 Trial Design Is the Real Competitive Moat in Bispecific Oncology - The Clinical Trial Vanguard
Roche’s Englumafusp Plus Glofitamab Combination Shows Why Phase 1 Trial Design Is the Real Competitive Moat in Bispecific Oncology The Clinical Trial Vanguard
Metachronous multiple primary cancers involving pulmonary non-Hodgkin lymphoma and bladder cancer: a case report - Frontiers
Metachronous multiple primary cancers involving pulmonary non-Hodgkin lymphoma and bladder cancer: a case report Frontiers
Non-Hodgkin lymphoma survivor thankful for clinical trial - UT MD Anderson
Non-Hodgkin lymphoma survivor thankful for clinical trial UT MD Anderson
Miami F Marcus Allen has non-Hodgkin lymphoma, out for season - ESPN
Miami F Marcus Allen has non-Hodgkin lymphoma, out for season ESPN
Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report - Frontiers
Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report Frontiers
Chidamide‑augmented BEAM conditioning and maintenance in first-remission T‑cell lymphoma: a single‑arm phase 2 experience - Nature
Chidamide‑augmented BEAM conditioning and maintenance in first-remission T‑cell lymphoma: a single‑arm phase 2 experience Nature
Advances in lymphoma treatment therapies and clinical trials - Penn Medicine
Advances in lymphoma treatment therapies and clinical trials Penn Medicine
Beyond the Nodes: Atypical Presentations of Non-Hodgkin's Lymphoma Across Organs - Cureus
Beyond the Nodes: Atypical Presentations of Non-Hodgkin's Lymphoma Across Organs Cureus
Roundup Non-Hodgkin’s Lymphoma Lawsuit [2026 Update] - robertkinglawfirm.com
Roundup Non-Hodgkin’s Lymphoma Lawsuit [2026 Update] robertkinglawfirm.com
Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma - CancerNetwork
Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma CancerNetwork
Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma | Signal Transduction and Targete - Nature
Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma | Signal Transduction and Targete Nature
Stage IV non-Hodgkin lymphoma survivor: Why I’m excited about UT MD Anderson coming to Austin - UT MD Anderson
Stage IV non-Hodgkin lymphoma survivor: Why I’m excited about UT MD Anderson coming to Austin UT MD Anderson
Breast Mass as an Atypical Presentation of Non-Hodgkin Lymphoma - Cureus
Breast Mass as an Atypical Presentation of Non-Hodgkin Lymphoma Cureus
FDA Orphan Drug Status Awarded to EO2463 in Indolent Non-Hodgkin Lymphoma - Targeted Oncology
FDA Orphan Drug Status Awarded to EO2463 in Indolent Non-Hodgkin Lymphoma Targeted Oncology
Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies - Frontiers
Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies Frontiers
The Evolving Roles of MRD and Molecular Genotyping in Non-Hodgkin Lymphoma - CancerNetwork
The Evolving Roles of MRD and Molecular Genotyping in Non-Hodgkin Lymphoma CancerNetwork
Pharmacokinetics of Odronextamab, A Bispecific T-Cell-Engaging Antibody, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - Wiley & Sons
Pharmacokinetics of Odronextamab, A Bispecific T-Cell-Engaging Antibody, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Wiley & Sons
Ureteral Involvement in Non-Hodgkin Lymphoma: A Rare Case Report With Diagnostic Challenges - Cureus
Ureteral Involvement in Non-Hodgkin Lymphoma: A Rare Case Report With Diagnostic Challenges Cureus
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes - GlobeNewswire
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes GlobeNewswire
Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma: From Clinical Trials to Clinical Practice - Journal of Nuclear Medicine
Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma: From Clinical Trials to Clinical Practice Journal of Nuclear Medicine
Non-Hodgkin’s lymphoma presenting as a retroperitoneal mass in the emergency department: a case report - Frontiers
Non-Hodgkin’s lymphoma presenting as a retroperitoneal mass in the emergency department: a case report Frontiers
Current treatment algorithm: diffuse large B cell lymphoma - Blood Cancer Journal - Nature
Current treatment algorithm: diffuse large B cell lymphoma - Blood Cancer Journal Nature
Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial - Nature
Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial Nature
Should Those with Non-Hodgkin Lymphoma Receive CAR T or Bispecifics? - CancerNetwork
Should Those with Non-Hodgkin Lymphoma Receive CAR T or Bispecifics? CancerNetwork
In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas - OncLive
In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas OncLive
Inequities in Access to Rituximab and Survival in Non-Hodgkin Lymphoma: A 20-Year Cohort Study from Nigeria - European Society of Medicine
Inequities in Access to Rituximab and Survival in Non-Hodgkin Lymphoma: A 20-Year Cohort Study from Nigeria European Society of Medicine
Hepatitis virus-associated B cell non-Hodgkin’s lymphoma involves dysregulated epigenetic and RNA-mediated regulatory gene expression and altered snoRNA transcription - Nature
Hepatitis virus-associated B cell non-Hodgkin’s lymphoma involves dysregulated epigenetic and RNA-mediated regulatory gene expression and altered snoRNA transcription Nature
CAR-NK Shows Long-Term Response in Waldenström Non-Hodgkin Lymphoma - Cure Today
CAR-NK Shows Long-Term Response in Waldenström Non-Hodgkin Lymphoma Cure Today
Dave Coulier Reveals New Cancer Diagnosis Months After Beating Non-Hodgkin Lymphoma - People.com
Dave Coulier Reveals New Cancer Diagnosis Months After Beating Non-Hodgkin Lymphoma People.com